Menu
Not yet recruiting NCT07439146

Risk of Pneumonia in Intubated Patients in Emergency Situations

Observational Pneumonia Orotracheal Intubation

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Pneumonia, Orotracheal Intubation. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

Orotracheal intubation in emergency medicine is a vital procedure for ensuring adequate oxygenation and ventilation in patients with respiratory distress or in shock. However, this procedure exposes patients to complications such as pneumonia. In the matter of fact, the urgency of the procedure means that it is not possible to wait until the patient's stomach is empty. Pneumonia significantly increase patient morbidity and mortality. Therapeutic management must be early and appropriate to improve the patient's prognosis. The aim of this study is to compare the rate of pneumonia occurring in patients intubated in emergency situations with that in patients intubated in non-emergency situations in all 2024. Health data will only collected from patient's medical records.

Primary outcome measures

  • Pneumonia rate in 48 hours after the start of orotracheal intubation. [Time frame: Hour 48]
Secondary outcome measures (9)
  • Pneumonia rate occuring 48 hours after the start of orotracheal intubation. [Time frame: 3 months]
  • Duration of mechanical ventilation [Time frame: Up to the end of mechanical ventilation (assessed up to 1 month)]
  • Duration of stay in intensive care [Time frame: Up to intensive care discharge (assessed up to 1 month)]
  • Duration of hospital stay [Time frame: Up to hospital discharge (assessed up to 3 months)]
  • Mortality rate [Time frame: Inclusion + 1 year]
  • Type of bacteria responsible for pneumonia [Time frame: The day of the diagnosis of pneumonia (assessed up to 1 month)]
  • Type of antibiotic administered for pneumonia [Time frame: Up to the last day of antibiotic treatment (assessed up to 3 months)]
  • Antibiotic doses administered for pneumonia [Time frame: Up to the last day of antibiotic treatment (assessed up to 3 months)]
  • Duration of antibiotic treament for pneumonia [Time frame: Up to the last day of antibiotic treatment (assessed up to 3 months)]

Eligibility criteria

Inclusion criteria

  • Adult man or woman
  • Emergency and non-emergency intubated patient in 2024
  • Patient hospitalized in intensive care following intubation in 2024

Exclusion criteria

  • Patient under guardianship, curatorship or safeguard of justice
  • Pregnant woman
  • Refusal to participate

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

France · 6 centers
  • CH Aurillac — Aurillac
  • CHU de Clermont-Ferrand, Clermont-Ferrand — Clermont-Ferrand
  • CH du Puy en Velay — Le Puy-en-Velay
  • CH de Montluçon — Montluçon
  • CH de Moulins — Moulins
  • CH de Vichy — Vichy

Identifiers

NCT: NCT07439146 · 2025_BOUILLON MINOIS_Pneumiot

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗